Javlor (Vinflunine)

Javlor is a Vinca alkaloid used in the treatment of urothelial carcinoma, a cancer of the bladder and urinary tract.

• Advanced urothelial carcinoma: provides disease control after platinum‑based chemotherapy failure.
• Metastatic urothelial carcinoma: offers a therapeutic option for patients with cancer spread beyond the bladder.
• Urothelial carcinoma (post‑platinum): used to extend survival in patients whose disease has progressed following standard platinum regimens.

• Vinflunine binds to tubulin, inhibiting microtubule assembly and dynamics. This disruption interferes with mitotic spindle formation, leading to cell‑cycle arrest at the G2/M phase and ultimately triggering apoptosis in rapidly dividing cancer cells.

Vinflunine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Neutropenia: reduced neutrophil count increasing infection risk.
• Anemia: lowered red blood cell levels causing fatigue.
• Nausea and vomiting: gastrointestinal upset.
• Constipation: decreased bowel movements.
• Fatigue: general weakness and tiredness.
• Alopecia: hair loss.

Serious or Rare Side Effects

• Severe neutropenia with febrile infection.
• Hemorrhage: bleeding complications.
• Cardiac toxicity: arrhythmias or reduced cardiac function.
• Severe hypersensitivity reactions: rash, bronchospasm, or anaphylaxis.
• Renal failure: impaired kidney function.
• Thromboembolic events: blood clots in veins or arteries.

Before initiating Vinflunine therapy, clinicians should assess patient-specific risk factors and monitor relevant parameters.

• Blood count monitoring: perform regular CBC to detect myelosuppression.
• Renal function assessment: evaluate creatinine clearance prior to each cycle.
• Hepatic function assessment: check liver enzymes for potential toxicity.
• Infection vigilance: avoid use in patients with active severe infections.
• Cardiac caution: monitor ECG in patients with known heart disease.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Vinflunine can interact with other medicines, altering its safety or effectiveness.

Major Interactions (Avoid)

• Concurrent Vinca alkaloids or taxanes: additive neurotoxicity.
• Strong CYP3A4 inhibitors (e.g., ketoconazole): increase vinflunine exposure.
• Potent CYP3A4 inducers (e.g., rifampicin): reduce therapeutic levels.
• Nephrotoxic agents (e.g., cisplatin): heightened renal risk.
• Anticoagulants (e.g., warfarin): increased bleeding tendency.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inhibitors (e.g., erythromycin): may raise plasma concentrations.
• Other myelosuppressive drugs (e.g., cyclophosphamide): enhanced bone‑marrow suppression.
• CYP2C9 or CYP2C19 inhibitors: potential modest increase in exposure.
• Diuretics: may affect renal clearance.
• Proton‑pump inhibitors: possible alteration of absorption dynamics.